Accelerated hyperfractionated radiotherapy within trimodality therapy concepts for stage IIIA/B non-small cell lung cancer: Markedly higher rate of pathologic complete remissions than with conventional fractionation

European Journal of Cancer

Volumn 49, Issue 9, 2013, Pages 2107-2115

  Pottgen C ^a   Eberhardt, W ^a   Graupner, B ^a   Theegarten, D ^a   Gauler, T ^a   Freitag, L ^b   Abu Jawad, J ^a   Wohlschlaeger, J ^a   Welter, S ^b   Stamatis, G ^b   Stuschke, M ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b RUHRLANDKLINIK   (Germany)

Author keywords

Accelerated hyperfractionation; Pathologic complete response; Radiochemotherapy; Stage III NSCLC; Trimodality

Indexed keywords

CISPLATIN;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; FEMALE; HUMAN; INDUCTION CHEMOTHERAPY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY, ADJUVANT; CISPLATIN; COMBINED MODALITY THERAPY; DOSE FRACTIONATION; ETOPOSIDE; FEMALE; HUMANS; INDUCTION CHEMOTHERAPY; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROPENSITY SCORE; TREATMENT OUTCOME;

EID: 84877687331     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2013.02.030     Document Type: Article

References (33)

1. K.S. Albain, R.S. Swann, and V.W. Rusch Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial Lancet 374 2009 379 386
2. J.P. van Meerbeeck, G.W. Kramer, and P.E. Van Schil Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer J Natl Cancer Inst 99 2007 442 450
3. A. Aupérin, C. Le Péchoux, and E. Rolland Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer J Clin Oncol 28 2010 2181 2190
4. A. Mauguen, C. Le Péchoux, and M.I. Saunders Hyperfractionated or accelerated radiotherapy in lung cancer: an individual patient data meta-analysis J Clin Oncol 30 2012 2788 2797
5. C. Pöttgen, W. Eberhardt, and A. Grannass Prophylactic cranial irradiation in operable stage IIIA non-small-cell lung cancer treated with neoadjuvant chemoradiotherapy: results from a German multicenter randomized trial J Clin Oncol 31 2007 4987 4992
6. C. Pöttgen, W. Eberhardt, and T. Gauler Intensified high-dose chemoradiotherapy with induction chemotherapy in patients with locally advanced non-small-cell lung cancer-safety and toxicity results within a prospective trial Int J Radiat Oncol Biol Phys 76 2010 809 815
7. W.E.E. Eberhardt, T.C. Gauler, and C. Le Pechoux Long-term survival of induction chemotherapy with three cycles cisplatin/paclitaxel followed by concurrent chemoradiation cis/etoposide and 45 Gy (1.5 Gy bid) plus surgery: phase II results (CISTAXOL) (abstract) J Clin Oncol 29 2011 (Suppl. abstr 7047)
8. W.E.E. Eberhardt, R. Hepp, and T.C. Gauler Competing risks analysis and long-term survival (LTS) of patients (pts) with locally advanced (LAD) stage III non-small cell lung cancer (NSCLC) treated on sequential trimodality trials J Thorac Oncol 6 2011 S376 (abstract)
9. M. Partridge, M. Ramos, A. Sardaro, and M. Brada Dose escalation for non-small cell lung cancer: analysis and modeling of published literature Radiother Oncol 99 2011 6 11
10. A. Van Baardwijk, G. Bosmans, and S.M. Bentzen Radiation dose prescription for non-small-cell lung cancer according to normal tissue dose constraints: an insilico clinical trial Int J Radiat Oncol Biol Phys 71 2008 1103 1110
11. J. Hadley, R. Yabroff, M.J. Barrett, D.F. Penson, C.S. Saigal, and A.L. Potosky Comparative effectiveness of prostate cancer treatments: evaluating statistical adjustment for confounding in observational data J Natl Cancer Inst 102 2010 1780 1793
12. T. Kurth, A.M. Walker, and R.J. Glynn Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity weighting under conditions of nonuniform effect Am J Epidemiol 163 2006 262 270
13. R.S. Leslie, and H. Ghomrawi Instrumental variable method for addressing selection bias D.E. Faries, A.C. Leon, J.M. Haro, R.L. Obenchain, Analysis of observational health care data using SAS® 2010 SAS Institute Inc. Cary, NC 131 149
14. M.K. Martel, R.K. Ten Haken, and M.B. Hazuka Estimation of tumor control probability model parameters from 3-D dose distributions of non-small cell lung cancer patients Lung Cancer 24 1999 31 37
15. J.I. Geh, S.J. Bond, S.M. Bentzen, and R. Glynne-Jones Systematic overview of preoperative (neoadjuvant) chemoradiotherapy trials in oesophageal cancer: evidence of a radiation and chemotherapy dose response Radiother Oncol 78 2006 236 244
16. S. Levegrün, A. Jackson, and M.J. Zelefsky Risk group dependence of dose-response for biopsy outcome after three-dimensional conformal radiation therapy of prostate cancer Radiother Oncol 63 2002 11 26
17. C.G. Willett, A.L. Schiller, H.D. Suit, H.J. Mankin, and A. Rosenberg The histologic response of soft tissue sarcoma to radiation therapy Cancer 60 1987 1500 1504
18. M. Thomas, C. Rübe, and P. Hoffknecht Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small-cell lung cancer Lancet Oncol 9 2008 636 648
19. W. Weder, S. Collaud, and W.E. Eberhardt Pneumonectomy is a valuable treatment option after neoadjuvant therapy for stage III non-small-cell lung cancer J Thorac Cardiovasc Surg 139 2010 1424 1430
20. G. Friedel, W. Budach, and J. Dippon Phase II trial of a trimodality regimen for stage III non-small-cell lung cancer using chemotherapy as induction treatment with concurrent hyperfractionated chemoradiation with carboplatin and paclitaxel followed by subsequent resection: a single-center study J Clin Oncol 28 2010 942 948
21. H. Yokomise, M. Gotoh, and T. Okamoto Induction chemoradiotherapy (carboplatin-taxane and concurrent 50-Gy radiation) for bulky cN2, N3 non-small cell lung cancer J Thorac Cardiovasc Surg 133 2007 1179 1185
22. M. Machtay, J.H. Lee, and J.P. Stevenson Two commonly used neoadjuvant chemoradiotherapy regimens for locally advanced stage III non-small cell lung carcinoma: long-term results and associations with pathologic response J Thorac Cardiovasc Surg 127 2004 108 113
23. G. Goeckenjan, H. Sitter, and M. Thomas Prevention, diagnosis, therapy, and follow-up of lung cancer: interdisciplinary guideline of the German Respiratory Society and the German Cancer Society Pneumologie 65 2011 39 59
24. M. Stuschke, and H.D. Thames Fractionation sensitivities and dose-control relations of head and neck carcinomas: analysis of the randomized hyperfractionation trials Radiother Oncol 51 1999 113 121
25. S. Senthi, F.J. Lagerwaard, C.J. Haasbeek, B.J. Slotman, and S. Senan Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis Lancet Oncol 13 2012 802 809
26. M.N. Corradetti, A.R. Haas, and R. Rengan Central-airway necrosis after stereotactic body radiation therapy N Engl J Med 366 2012 2327 2329
27. A. Chi, Z. Liao, N.P. Nguyen, J. Xu, B. Stea, and R. Komaki Systemic review of the patterns of failure following stereotactic body radiation therapy in early-stage non-small-cell lung cancer: clinical implications Radiother Oncol 94 2010 1 11
28. B.P. Rowe, D.J. Boffa, L.D. Wilson, A.W. Kim, F.C. Detterbeck, and R.H. Decker Stereotactic body radiotherapy for central lung tumors J Thorac Oncol 7 2012 1394 1399
29. R. Timmerman, R. McGarry, and C. Yiannoutsos Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer J Clin Oncol 24 2006 4833 4839
30. A. Rolle, R. Günzel, and U. Pachmann Increase in number of circulating disseminated epithelial cells after surgery for non-small cell lung cancer monitored by MAINTRAC(R) is a predictor for relapse: a preliminary report World J Surg Oncol 3 2005 18
31. L.M. Backhus, E. Sievers, and G.Y. Lin Perioperative cyclooxygenase 2 inhibition to reduce tumor cell adhesion and metastatic potential of circulating tumor cells in non-small cell lung cancer J Thorac Cardiovasc Surg 132 2006 297 303
32. M. Ge, D. Shi, Q. Wu, M. Wang, and L. Li Fluctiation of circulating tumor cells in patients with lung cancer by real-time fluorescent quantitative-PCR approach before and after radiotherapy J Cancer Res Ther 1 2005 221 226
33. A. van Baardwijk, B. Reymen, and S. Wanders Mature results of a phase II trial on individualised accelerated radiotherapy based on normal tissue constraints in concurrent chemo-radiation for stage III non-small cell lung cancer Eur J Cancer 48 2012 2339 2346